While new diagnoses of diabetes in adults have slowed in recent years, the pandemic may reverse this trend. Physicians, payers, and pharmaceutical companies all can play a part in mitigating the long-term effects on persons with diabetes. Precision's Cynthia Miller details how these stakeholders can collaborate to mitigate future damage.
In 2021, PRECISIONvalue launched a proprietary survey of the care management ecosystem (including payers and health systems) and found diabetes to be one of the top conditions for which individuals are referred for care management.
Join us on Thursday, 10/21 @ 1:00 PM ET for this engaging webinar with PQA Quality Forum, featuring PRECISIONvalue's Maureen Hennessey.
In 2021, COVID-19 and its ongoing impact on the healthcare, scientific, political, and social climate continued to be the dominant transformative lens through which we view trends in the following areas: healthcare costs, clinical practice and scientific innovation, US healthcare policy, value-based care, and pandemic/endemic management.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
